UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 12, 2004
CHAD THERAPEUTICS, INC.
| California | 001-12214 | 34-1659805 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) | ||
| 21622 Plummer Street, Chatsworth, California | 91311 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (818) 882-0883
Not Applicable
| ITEM 9. REGULATION FD DISCLOSURE (INFORMATION PROVIDED UNDER ITEM 12 — RESULTS OF OPERATIONS AND FINANCIAL CONDITION) | ||||||||
| SIGNATURE | ||||||||
| EXHIBIT 99.1 | ||||||||
ITEM 9. REGULATION FD DISCLOSURE (INFORMATION PROVIDED UNDER ITEM 12 — RESULTS OF OPERATIONS AND FINANCIAL CONDITION)
Pursuant to Securities and Exchange Commission Release No. 33-8216 dated March 27, 2003, the following information is being furnished under Item 12 of Form 8-K.
On February 12, 2004, CHAD Therapeutics issued a press release announcing its third quarter and nine month fiscal 2004 operating results. A copy of the press release is furnished herewith as Exhibit 99.1 to this Report.
[Remainder of Page Left Intentionally Blank.]
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CHAD THERAPEUTICS, INC., a California corporation |
||||
| Date: February 12, 2004 | By | /s/ Earl L. Yager | ||
| Earl L. Yager President and Chief Financial Officer |
||||
3